Myhep All supplier USA

Myhep All supplier USA MyHep All is a breakthrough, all-oral antiviral medication used to treat all genotypes of chronic Hepatitis C infection. It contains Sofosbuvir (400 mg) and Velpatasvir (100 mg), offering a complete, once-daily treatment solution with a high cure rate and minimal side effects. MyHep All is a powerful fixed-dose combination medication manufactured by Mylan Pharmaceuticals for the treatment of chronic Hepatitis C in adults. It contains Sofosbuvir 400 mg, a nucleotide polymerase inhibitor, and Velpatasvir 100 mg, an NS5A inhibitor. Together, these direct-acting antivirals (DAAs) stop the virus from multiplying and eliminate it from the body. Approved for treatment across all six major genotypes (genotype 1-6) of HCV, MyHep All simplifies therapy by offering a pangenotypic, once-daily oral tablet—no need for interferon or ribavirin in most cases. The standard treatment duration is 12 weeks, often resulting in a sustained virologic response (SVR), which is considered a cure.